Aaron Wealth Advisors LLC Purchases New Shares in IQVIA Holdings Inc. (NYSE:IQV)

Aaron Wealth Advisors LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 1,003 shares of the medical research company’s stock, valued at approximately $238,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Ballentine Partners LLC lifted its holdings in IQVIA by 11.8% during the 1st quarter. Ballentine Partners LLC now owns 1,424 shares of the medical research company’s stock worth $360,000 after buying an additional 150 shares in the last quarter. Central Valley Advisors LLC grew its position in IQVIA by 9.5% during the 1st quarter. Central Valley Advisors LLC now owns 5,612 shares of the medical research company’s stock worth $1,419,000 after purchasing an additional 488 shares during the last quarter. Riverview Trust Co purchased a new position in IQVIA during the 1st quarter worth $32,000. Wealth Enhancement Advisory Services LLC grew its position in IQVIA by 5.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,898 shares of the medical research company’s stock worth $1,492,000 after purchasing an additional 300 shares during the last quarter. Finally, Cypress Wealth Services LLC lifted its stake in shares of IQVIA by 5.3% in the 1st quarter. Cypress Wealth Services LLC now owns 1,101 shares of the medical research company’s stock worth $278,000 after acquiring an additional 55 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Robert W. Baird raised their target price on shares of IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research note on Friday, September 20th. Royal Bank of Canada began coverage on shares of IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 target price for the company. Truist Financial reduced their price objective on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price objective for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Finally, Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $267.87.

IQVIA Trading Up 1.2 %

Shares of IQV stock opened at $236.69 on Monday. The stock has a market cap of $43.15 billion, a price-to-earnings ratio of 30.74, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The firm’s 50 day moving average price is $239.08 and its two-hundred day moving average price is $231.08.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the previous year, the company posted $2.22 earnings per share. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.